Results 1 to 10 of about 675,523 (296)

Prime-Boost Immunisation Strategies for Tuberculosis

Microbes and Infection, 2005
Vaccines against intracellular pathogens such as Mycobacterium tuberculosis need to induce strong cellular immune responses. Heterologous prime-boost immunisation strategies induce higher levels of both CD4+ and CD8+ T cells than homologous boosting with the same vector. Recombinant pox-viruses are particularly good at boosting previously primed T cell
Helen McShane, Adrian V. S. Hill
exaly   +5 more sources

Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates

Frontiers in Immunology, 2021
Heterologous prime-boost immunization regimens are a common strategy for many vaccines. DNA prime rAd5-GP boost immunization has been demonstrated to protect non-human primates against a lethal challenge of Ebola virus, a pathogen that causes fatal ...
Hadar Marcus, Emily Thompson, Yan Zhou, Michael Bailey, Mitzi M. Donaldson, Daphne A. Stanley, Clement Asiedu, Kathryn E. Foulds, Mario Roederer, Juan I. Moliva, Nancy J. Sullivan   +10 more
doaj   +3 more sources

Orf virus DNA prime-protein boost strategy is superior to adenovirus-based vaccination in mice and sheep [PDF]

Frontiers in Immunology, 2023
Contagious ecthyma (Orf), an acute and highly contagious zoonosis, is prevalent worldwide. Orf is caused by Orf virus (ORFV), which mainly infects sheep/goats and humans. Therefore, effective and safe vaccination strategies for Orf prevention are needed.
Yan Wang, Shihui Sun, Kui Zhao, Le Du, Xinyue Wang, Wenqi He, Feng Gao, Deguang Song, Jiyu Guan   +8 more
doaj   +2 more sources

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination

Vaccines, 2023
With concerns about the efficacy of repeat annual influenza vaccination, it is important to better understand the impact of priming vaccine immunity and develop an effective vaccination strategy. Here, we determined the impact of heterologous prime-boost
Noopur Bhatnagar, Ki-Hye Kim, Jeeva Subbiah, Sakinah Muhammad-Worsham, Bo Ryoung Park, Rong Liu, Phillip Grovenstein, Bao-Zhong Wang, Sang-Moo Kang   +8 more
doaj   +2 more sources

Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost

Frontiers in Immunology, 2021
The efficacy of COVID-19 vaccines appears to depend in complex ways on the vaccine dosage and the interval between the prime and boost doses. Unexpectedly, lower dose prime and longer prime-boost intervals have yielded higher efficacies in clinical ...
Amar K. Garg, Soumya Mittal, Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit, Narendra M. Dixit   +5 more
doaj   +3 more sources

Heterologous Prime–Boost Vaccination with GRA35-Encoding DNA and mRNA Vaccines Enhances Protective Immunity Against Toxoplasma gondii Infection in Mouse Models [PDF]

Microorganisms
Toxoplasma gondii is an obligate intracellular protozoan parasite that causes toxoplasmosis, posing a significant threat to human health and livestock production worldwide.
Sisi Chen, Rui Li, Yanyan Zhu, Jie Sun, Jia Chen   +4 more
doaj   +2 more sources

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs. [PDF]

Vaccines (Basel), 2023
Three commercial vaccines are administered in domestic livestock farms for routine vaccination to aid for foot-and-mouth disease (FMD) control in Korea. Each vaccine contains distinct combinations of inactivated serotype O and A FMD virus (FMDV) antigens: O/Manisa + O/3039 + A/Iraq formulated in a double oil emulsion (DOE), O/Primorsky + A/Zabaikalsky ...
Kim J, Lee SH, Kim HH, Park JH, Park CK.
europepmc   +4 more sources

Efficacy and immunogenicity of rKVAC85B in a BCG prime-boost regimen against H37Rv and HN878 Mycobacterium tuberculosis strains. [PDF]

PLoS ONE
Mycobacterium tuberculosis infection accounted for 1.3 million deaths worldwide in 2022. Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB); however, it has limited protective efficacy in adults.
Eunkyung Shin, Jin-Seung Yun, Young-Ran Lee, Hye-Ran Cha, Soo-Min Kim, Sung-Jae Shin, Sang-Won Lee, Gyung Tae Chung, Dokeun Kim, Jung Sik Yoo, Jong-Seok Kim, Hye-Sook Jeong   +11 more
doaj   +2 more sources

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

Viruses, 2010
Currently, there are more than 30 million people infected with HIV-1 and thousands more are infected each day. Vaccination is the single most effective mechanism for prevention of viral disease, and after more than 25 years of research, one vaccine has ...
Julia L. Hurwitz, Patricia Flynn, Pamela Freiden, Nanna Howlett, Timothy D. Lockey, Kristen Branum, Karen S. Slobod, Bart G. Jones, Robert Sealy, Scott A. Brown, Sherri L. Surman   +10 more
doaj   +3 more sources

Heterologous Prime-boost COVID-19 Vaccination

JK Science, 2021
There is a significant recent international interest in heterologous prime-boost COVID-19 vaccination. It may prove useful in avoiding the supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out in any country including ...
Vishal R. Tandon, Annil Mahajan
doaj   +1 more source